IntelliPharmaCeutics International (IntelliPharmaCeutics International) Forward Dividend Yield % : 0.00% (As of May. 16, 2024)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Forward Dividend Yield %?

As of today (2024-05-16), the Forward Annual Dividend Yield of IntelliPharmaCeutics International is 0.00%.

As of today (2024-05-16), the Trailing Annual Dividend Yield of IntelliPharmaCeutics International is 0.00%.

IPCIF's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

IntelliPharmaCeutics International's Dividends per Share for the three months ended in Aug. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of IntelliPharmaCeutics International's Forward Dividend Yield %

For the Biotechnology subindustry, IntelliPharmaCeutics International's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Forward Dividend Yield % falls into.

IntelliPharmaCeutics International Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

IntelliPharmaCeutics International (OTCPK:IPCIF) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

IntelliPharmaCeutics International Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.